Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

614 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera.
Barone M, Barone M, Ricci F, Auteri G, Corradi G, Fabbri F, Papa V, Bandini E, Cenacchi G, Tazzari PL, Vianelli N, Turroni S, Cavo M, Palandri F, Candela M, Catani L. Barone M, et al. Among authors: cavo m. Front Oncol. 2021 Nov 25;11:715217. doi: 10.3389/fonc.2021.715217. eCollection 2021. Front Oncol. 2021. PMID: 34900671 Free PMC article.
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, Martinelli G, Catani L, Baccarani M, Vianelli N. Palandri F, et al. Among authors: cavo m. Leukemia. 2015 Jun;29(6):1344-9. doi: 10.1038/leu.2015.87. Epub 2015 Mar 24. Leukemia. 2015. PMID: 25801912
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms.
Polverelli N, Catani L, Vianelli N, Baccarani M, Cavo M, Palandri F. Polverelli N, et al. Among authors: cavo m. Ann Hematol. 2015 Sep;94(9):1585-7. doi: 10.1007/s00277-015-2397-9. Epub 2015 May 16. Ann Hematol. 2015. PMID: 25975976 No abstract available.
Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly.
Palandri F, Polverelli N, Breccia M, Nicolino B, Vitolo U, Alimena G, Cavo M, Vianelli N, Benevolo G. Palandri F, et al. Among authors: cavo m. Br J Haematol. 2016 Jul;174(1):160-2. doi: 10.1111/bjh.13758. Epub 2015 Oct 28. Br J Haematol. 2016. PMID: 26507357 Free article. No abstract available.
Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.
Sollazzo D, Forte D, Polverelli N, Romano M, Perricone M, Rossi L, Ottaviani E, Luatti S, Martinelli G, Vianelli N, Cavo M, Palandri F, Catani L. Sollazzo D, et al. Among authors: cavo m. Oncotarget. 2016 Jul 12;7(28):43974-43988. doi: 10.18632/oncotarget.9949. Oncotarget. 2016. PMID: 27304059 Free PMC article.
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.
Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, Martinelli G, Lewis RE, Vianelli N, Cavo M, Palandri F. Polverelli N, et al. Among authors: cavo m. Am J Hematol. 2017 Jan;92(1):37-41. doi: 10.1002/ajh.24572. Epub 2016 Nov 12. Am J Hematol. 2017. PMID: 27701770 Free article.
614 results